• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿仑单抗诱导的格雷夫斯病患者发生甲状腺风暴:一例报告

Thyroid Storm in a Patient With Alemtuzumab-Induced Graves' Disease: A Case Report.

作者信息

AlShehri Sara, Alajmi Sarah, Ekhzaimy Aishah, Aldawas Sadeem, Alalwan Maryam

机构信息

Endocrinology, Diabetes and Metabolism, King Saud University, Riyadh, SAU.

Internal Medicine/Adult Endocrinology, King Saud University, Riyadh, SAU.

出版信息

Cureus. 2022 Apr 28;14(4):e24570. doi: 10.7759/cureus.24570. eCollection 2022 Apr.

DOI:10.7759/cureus.24570
PMID:35651398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9138563/
Abstract

Thyroid storm (TS) is a rare and life-threatening medical emergency, most commonly caused by Graves' disease (GD). GD can be induced by immune reconstitution therapy (IRT) such as alemtuzumab (ALZ), a humanized monoclonal antibody against CD52, which is shown to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Here, we present a rare case of TS developing in a 39-year-old female with ALZ-induced GD, managed with antithyroid medication followed by thyroidectomy. There is some evidence that ALZ-induced GD may behave less aggressively than conventional GD. However, physicians should be aware that severe thyrotoxicosis and thyroid storm can happen, which requires prompt recognition and aggressive therapy.

摘要

甲状腺风暴(TS)是一种罕见且危及生命的医疗急症,最常见由格雷夫斯病(GD)引起。GD可由免疫重建治疗(IRT)诱发,如阿仑单抗(ALZ),一种抗CD52的人源化单克隆抗体,已证明其在治疗复发缓解型多发性硬化症(RRMS)方面有效。在此,我们报告一例罕见病例,一名39岁女性因ALZ诱发GD而发生甲状腺风暴,先采用抗甲状腺药物治疗,随后进行了甲状腺切除术。有证据表明,ALZ诱发的GD可能比传统GD的侵袭性小。然而,医生应意识到严重甲状腺毒症和甲状腺风暴可能发生,这需要及时识别并积极治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/13718af608ff/cureus-0014-00000024570-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/ecd4dbc0f5bd/cureus-0014-00000024570-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/fbc25adc2090/cureus-0014-00000024570-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/ece5e2d8ef07/cureus-0014-00000024570-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/13718af608ff/cureus-0014-00000024570-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/ecd4dbc0f5bd/cureus-0014-00000024570-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/fbc25adc2090/cureus-0014-00000024570-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/ece5e2d8ef07/cureus-0014-00000024570-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c662/9138563/13718af608ff/cureus-0014-00000024570-i04.jpg

相似文献

1
Thyroid Storm in a Patient With Alemtuzumab-Induced Graves' Disease: A Case Report.阿仑单抗诱导的格雷夫斯病患者发生甲状腺风暴:一例报告
Cureus. 2022 Apr 28;14(4):e24570. doi: 10.7759/cureus.24570. eCollection 2022 Apr.
2
Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.阿仑单抗诱导复发缓解型多发性硬化症严重眼肌病。
J Neurol. 2024 Jan;271(1):486-496. doi: 10.1007/s00415-023-11995-6. Epub 2023 Sep 29.
3
Management of Severe Graves' Hyperthyroidism in Pregnancy Following Immune Reconstitution Therapy in Multiple Sclerosis.多发性硬化症免疫重建治疗后妊娠期间重度格雷夫斯甲亢的管理
J Endocr Soc. 2021 Mar 17;5(6):bvab044. doi: 10.1210/jendso/bvab044. eCollection 2021 Jun 1.
4
Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.接受阿仑单抗治疗的多发性硬化症患者的自身免疫性甲状腺疾病:选择性抗促甲状腺激素受体免疫反应的一个实例
Front Endocrinol (Lausanne). 2017 Sep 28;8:254. doi: 10.3389/fendo.2017.00254. eCollection 2017.
5
Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.多发性硬化症患者使用阿仑单抗治疗后的甲状腺自身免疫:一项前瞻性研究。
Clin Exp Med. 2023 Oct;23(6):2885-2894. doi: 10.1007/s10238-022-00981-3. Epub 2023 Jan 15.
6
Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.在原发性进行性多发性硬化症中,使用奥瑞珠单抗后Graves病自发缓解。
Endocr Regul. 2021 Sep 13;55(3):169-173. doi: 10.2478/enr-2021-0018.
7
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.阿仑单抗诱导的多发性硬化症甲状腺事件:系统评价和荟萃分析。
J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26.
8
Alemtuzumab-Induced Autoimmune Thyroid Dysfunction.阿仑单抗诱导的自身免疫性甲状腺功能障碍。
Cureus. 2022 Mar 1;14(3):e22751. doi: 10.7759/cureus.22751. eCollection 2022 Mar.
9
[Alemtuzumab-induced Graves' disease].[阿仑单抗诱发的格雷夫斯病]
Probl Endokrinol (Mosk). 2023 Jun 30;69(3):51-57. doi: 10.14341/probl13238.
10
Graves' disease after treatment with alemtuzumab for multiple sclerosis.多发性硬化症用阿仑单抗治疗后发生格雷夫斯病。
Hormones (Athens). 2015 Jan-Mar;14(1):148-53. doi: 10.14310/horm.2002.1501.

引用本文的文献

1
Data Analysis and Systematic Scoping Review on the Pathogenesis and Modalities of Treatment of Thyroid Storm Complicated with Myocardial Involvement and Shock.甲状腺风暴合并心肌受累及休克的发病机制与治疗方式的数据分析及系统范围综述
Diagnostics (Basel). 2023 Sep 23;13(19):3028. doi: 10.3390/diagnostics13193028.

本文引用的文献

1
Successful Stabilization of Thyroid Storm Precipitated by Medication Noncompliance and Complicated Urinary Tract Infection: A Case Report.因药物治疗依从性差和复杂尿路感染引发的甲状腺危象成功得到控制:一例报告
Cureus. 2022 Jan 9;14(1):e21048. doi: 10.7759/cureus.21048. eCollection 2022 Jan.
2
A storm off the charts: a case of thyroid storm due to thyrotoxicosis factitia.一场超乎寻常的风暴:一例人为甲状腺毒症所致的甲状腺危象
Intern Med J. 2021 May;51(5):806-807. doi: 10.1111/imj.15323.
3
2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.
2019年欧洲甲状腺协会免疫重建治疗后甲状腺功能障碍管理指南。
Eur Thyroid J. 2019 Jul;8(4):173-185. doi: 10.1159/000500881. Epub 2019 Jul 4.
4
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.阿仑单抗诱导的多发性硬化症甲状腺事件:系统评价和荟萃分析。
J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26.
5
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.阿仑单抗治疗复发型多发性硬化症(CARE-MS II)5年随访:疗效与安全性结果
Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.
6
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.2016年美国甲状腺协会甲状腺功能亢进症及其他甲状腺毒症病因的诊断和管理指南。
Thyroid. 2016 Oct;26(10):1343-1421. doi: 10.1089/thy.2016.0229.
7
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.阿仑单抗治疗多发性硬化症:作用机制及其他
Int J Mol Sci. 2015 Jul 20;16(7):16414-39. doi: 10.3390/ijms160716414.
8
Product licences for alemtuzumab and multiple sclerosis.阿仑单抗与多发性硬化症的产品许可证。
Lancet. 2014 Mar 8;383(9920):867-8. doi: 10.1016/S0140-6736(14)60440-2.
9
Thyroid storm: an updated review.甲状腺危象:最新综述
J Intensive Care Med. 2015 Mar;30(3):131-40. doi: 10.1177/0885066613498053. Epub 2013 Aug 5.
10
Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys.基于全国性调查的甲状腺危象的诊断标准、临床特征和发生率。
Thyroid. 2012 Jul;22(7):661-79. doi: 10.1089/thy.2011.0334. Epub 2012 Jun 12.